title: Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.
abstract: BACKGROUND
  Dose intensification of chemotherapy has improved outcome for younger adults with de novo acute lymphoblastic leukemia (ALL). Novel formulations of standard chemotherapy agents may further reduce the incidence of disease recurrence after frontline chemotherapy. Vincristine (VCR) sulfate liposomes injection (VSLI) is a sphingomyelin/cholesterol nanoparticle encapsulated VCR formulation that improves the pharmacokinetic profile of VCR without augmenting neurotoxicity.
  
  
  METHODS
  A phase 1 trial of weekly, intravenous VSLI at 1.5 mg/m(2), 1.825 mg/m(2), 2.0 mg/m(2), 2.25 mg/m(2), or 2.4 mg/m(2) was conducted to determine the maximum tolerated dose (MTD) using a standard, 3 + 3 dose-escalation design. Dexamethasone (40 mg) was given on Days 1 through 4 and on Days 11 through 14 of each 4-week cycle.
  
  
  RESULTS
  Thirty-six adults with relapsed/refractory ALL, all previously treated with conventional VCR, received at least 1 dose of VSLI. The MTD of VSLI was 2.25 mg/m(2) based on dose-limiting toxicities of grade 3 motor neuropathy, grade 4 seizure, and grade 4 hepatotoxicity in 1 patient each at the 2.4 mg/m(2) dose level. The most common toxicities attributed to VSLI included peripheral neuropathy (55%) and constipation (53%). A complete response (CR) was achieved in 7 of 36 patients (19%) based on an intent-to-treat analysis; the CR rate was 29% for the 14 patients who underwent therapy as their first salvage attempt. Four of 7 patients who achieved a CR underwent subsequent allogeneic stem cell transplantation in remission.
  
  
  CONCLUSIONS
  In this study, VSLI plus dexamethasone appeared to be an effective salvage therapy option for relapsed/refractory ALL. A phase 2, international, multicenter clinical trial assessing the efficacy of single-agent VSLI as second salvage therapy for patients with previously treated ALL is underway.
authors.affiliation: Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. debthomas@mdanderson.org
authors.forename: Deborah A
authors.initials: DA
authors.lastname: Thomas
authors.forename: Hagop M
authors.initials: HM
authors.lastname: Kantarjian
authors.forename: Wendy
authors.initials: W
authors.lastname: Stock
authors.forename: Leonard T
authors.initials: LT
authors.lastname: Heffner
authors.forename: Stefan
authors.initials: S
authors.lastname: Faderl
authors.forename: Guillermo
authors.initials: G
authors.lastname: Garcia-Manero
authors.forename: Alessandra
authors.initials: A
authors.lastname: Ferrajoli
authors.forename: William
authors.initials: W
authors.lastname: Wierda
authors.forename: Sherry
authors.initials: S
authors.lastname: Pierce
authors.forename: Biao
authors.initials: B
authors.lastname: Lu
authors.forename: Steven R
authors.initials: SR
authors.lastname: Deitcher
authors.forename: Susan
authors.initials: S
authors.lastname: O'Brien
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008081:Liposomes; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy; D012008:Recurrence; D016879:Salvage Therapy; D014750:Vincristine / Q000008:administration & dosage*
chemical_list: D008081:Liposomes; D014750:Vincristine; D003907:Dexamethasone
references.citation: Cancer Res. 1990 Feb 1;50(3):575-9
references.pmid: 2297698
references.citation: J Pediatr. 1994 Oct;125(4):642-9
references.pmid: 7931891
references.citation: Cancer Res. 1994 Jun 1;54(11):2830-3
references.pmid: 8187061
references.citation: Cancer Chemother Pharmacol. 1999;44(3):203-9
references.pmid: 10453721
references.citation: J Pharmacol Exp Ther. 2001 Sep;298(3):1206-12
references.pmid: 11504822
references.citation: Blood. 2008 Sep 1;112(5):1646-54
references.pmid: 18502832
references.citation: Br J Cancer. 1995 Mar;71(3):482-8
references.pmid: 7880728
references.citation: Ann Oncol. 2000 Jan;11(1):69-72
references.pmid: 10690390
references.citation: Cancer. 2006 Jan 1;106(1):120-7
references.pmid: 16331634
references.citation: Med Toxicol. 1986 Nov-Dec;1(6):421-7
references.pmid: 3540519
references.citation: Cancer. 1999 Oct 1;86(7):1216-30
references.pmid: 10506707
references.citation: Biochim Biophys Acta. 1993 Nov 7;1152(2):253-8
references.pmid: 8218326
references.citation: N Engl J Med. 1972 Jun 22;286(25):1369-70
references.pmid: 5027400
references.citation: Cancer. 2009 Dec 1;115(23):5490-8
references.pmid: 19708032
references.citation: J Clin Oncol. 1999 Feb;17(2):697-705
references.pmid: 10080616
references.citation: Cancer. 2008 Dec 1;113(11):3186-91
references.pmid: 18846563
references.citation: Int J Cancer. 2004 Jul 10;110(5):767-74
references.pmid: 15146568
references.citation: Cancer Res. 1976 Apr;36(4):1499-502
references.pmid: 1260766
references.citation: Br J Cancer. 1995 Oct;72(4):896-904
references.pmid: 7547237
references.citation: Cancer Res. 1977 Aug;37(8 Pt 1):2603-7
references.pmid: 872088
references.citation: Biochem Biophys Res Commun. 1972 May 26;47(4):685-91
references.pmid: 5026289